Ultra-high purity MediQ7® 페이지 정보 Writer ADMIN Date22-01-14 12:00 Hit2,100 본문 Ultra-high concentrated MediQ7® Pure (>96% MK7 conc.), derived from fermentation, has been introduced to the market by GF Fermentech. Due to the high demand of the market and confidence derived from GF Fermentech’s core technology, MediQ7® Pure has been added to the product list, expanding the product line to provide more options to clients interested in highly concentrated Vitamin K2 MK-7. Aimed at providing more varied options to clients, GF Fermentech’s ability to develop a new highly concentrated Vitamin K2 MK-7 is a result of research and investment over the long term. The new MediQ7® Pure has a concentration of > 96% and 99.9% of trans-type Menaquinone-7, the active form of Vitamin K2. MediQ7® Pure will enable clients to have more flexibility on formulation and to expand their brand line and therefore set to lead the market with innovative Vitamin K2 MK-7 in the market. Vitamin K2 MK-7 has proven its efficiency in benefits in bone health and heart health in many studies. Known as a vitamin essential for carboxylating Osteocalcin and MGP -Matrix Gla Protein- proteins, Vitamin K2 MK-7 activates Osteocalcin which transfers calcium to the bones and lets the bones absorb calcium. By the same principle, when MGP gets activated by Vitamin K2 MK-7, it inhibits calcium accumulation in blood vessels of arteries, kidneys, and brain which can therefore prevent cardiovascular diseases. When there is a deficiency of elements, such as Vitamin K2, that regulate calcium metabolism, the homeostasis of calcium in the body dysfunctions, building up calcium deposits in the blood vessels and forms calcium plaques. Due to these problems, it is vital to consume vitamin K2, which prevents calcification of blood vessels by allowing calcium liberated in the blood to be absorbed into the bones. Since Vitamin K2 is commonly applied with health supplements like Calcium and Vitamin D3 thanks to its proven effects, the market is further expected to surge exponentially.For more information, please contact gftinfo@genofocus.com Next Previous List